NovaBay Pharmaceuticals to Present at 29th Annual ROTH Conference
March 07 2017 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a
biopharmaceutical company focusing on commercializing prescription
Avenova® lid and lash hygiene for the domestic eye care market,
announces that Chairman, President and CEO Mark M. Sieczkarek is
scheduled to present a corporate overview at the 29th Annual ROTH
Conference on Tuesday, March 14, 2017, at 3:30 p.m. Pacific time
(6:30 p.m. Eastern time). The conference is being held at The
Ritz-Carlton, Laguna Niguel in Dana Point, Calif.
A live webcast and replay will be available on the Investors
section of the Company's website at
http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®Avenova is formulated with Neutrox®, which
is cleared by the U.S. Food and Drug Administration (FDA) as a
510(k) medical device. Neutrox is NovaBay’s commercial name for its
proprietary pure hypochlorous acid. Data from a multicenter
clinical study show that Avenova reduced bacterial load, the
underlying cause of blepharitis, on ocular skin surface by more
than 90%. Laboratory tests show that hypochlorous acid has potent
antimicrobial activity in solution yet is non-toxic to mammalian
cells and also neutralizes bacterial toxins. Avenova is marketed to
optometrists and ophthalmologists throughout the U.S. by NovaBay’s
direct salesforce. It is accessible from more than 90% of retail
pharmacies in the U.S. through agreements with McKesson
Corporation, Cardinal Health and AmerisourceBergen.
Stay informed on NovaBay's
progress:Download our Mobile InvestorApp from
the Apple Store or Google PlayLike us
on FacebookFollow us on TwitterConnect
with NovaBay on LinkedInJoin us on
Google+Visit NovaBay's Website
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170307005405/en/
NovaBay ContactsFor NovaBay
Avenova purchasing information, please contact:Email usCall us:
1-800-890-0329www.Avenova.comorFrom the
CompanyThomas J. Paulson, 510-899-8809Chief Financial
OfficerContact TomorInvestor
Contact:LHAJody Cain, 310-691-7100Jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024